SRH Advisors’s Gilead Sciences GILD Stock Holding History

SRH Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.5K	Hold	550	–	–	0.02%	125
2026 Q1	$76.7K	Hold	550	–	–	0.02%	115
2025 Q4	$67.5K	Hold	550	–	–	0.02%	120
2025 Q3	$61K	Hold	550	–	–	0.02%	122
2025 Q2	$61K	Hold	550	–	–	0.02%	117
2025 Q1	$61.6K	Hold	550	–	–	0.02%	115
2024 Q4	$50.8K	Hold	550	–	–	0.02%	127
2024 Q3	$46.1K	Hold	550	–	–	0.01%	128
2024 Q2	$37.7K	Hold	550	–	–	0.01%	133
2024 Q1	$40.3K	Hold	550	–	–	0.01%	137
2023 Q4	$44.6K	Hold	550	–	–	0.02%	130
2023 Q3	$41.2K	Hold	550	–	–	0.02%	124
2023 Q2	$45.6K	Hold	550	–	–	0.02%	120
2023 Q1	$46K	Hold	550	–	–	0.02%	120
2022 Q4	$47K	Hold	550	–	–	0.03%	119
2022 Q3	$34K	Hold	550	–	–	0.04%	137
2022 Q2	$34K	Hold	550	–	–	0.04%	133
2022 Q1	$33K	Hold	550	–	–	0.04%	150
2021 Q4	$40K	Hold	550	–	–	0.05%	141
2021 Q3	$38K	Hold	550	–	–	0.05%	142
2021 Q2	$38K	Hold	550	–	–	0.05%	141
2021 Q1	$36K	Hold	550	–	–	0.05%	130
2020 Q4	$32K	Hold	550	–	–	0.05%	135
2020 Q3	$35K	Hold	550	–	–	0.07%	117
2020 Q2	$42K	Buy	+550	New	+$42.1K	0.1%	89

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SRH Advisors's GILD Position: Q2 2026 in Review

SRH Advisors held its Gilead Sciences (GILD) position steady in Q2 2026 at 550 shares worth $69.5K. The position accounts for 0.02% of the portfolio, ranked #125.

SRH Advisors first reported a position in GILD in Q2 2020 and has held it in 25 quarters since. The position peaked at $76.7K in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

SRH Advisors held 550 shares of Gilead Sciences worth $69.5K as of Q2 2026.
SRH Advisors left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up 0.02% of SRH Advisors's portfolio in Q2 2026, its #125 holding.
SRH Advisors first reported a position in Gilead Sciences in Q2 2020 and has held it in 25 quarters since.
SRH Advisors's Gilead Sciences position peaked at $76.7K in Q1 2026.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on SRH Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.